Navigation Links
Mount Sinai leads Consortium of Food Allergy Research with $29.9 million grant
Date:8/12/2010

Mount Sinai School of Medicine today announced that the National Institutes of Health (NIH) has renewed its funding of the Consortium of Food Allergy Research (CoFAR), providing an additional $29.9 million toward genetic research and the prevention and treatment of food allergy. Mount Sinai is the primary research site for CoFAR, leading seven other institutions around the country.

Under the renewed grant, Mount Sinai researchers will continue several clinical trials evaluating immunotherapies for peanut and egg allergy. In two of the studies, researchers are determining whether an extract of peanut protein under the tongue or ingesting increasing amounts of egg protein improves tolerance. In another trial, researchers administer gradually increased doses of peanut protein to patients in a suppository to treat the allergy. The Mount Sinai team will also initiate a new trial studying the use of a peanut protein patch applied to the skin to treat peanut allergy. CoFAR is also conducting an observational study that has enrolled more than 500 infants to determine what factors worsen or improve their allergies.

"We are excited about the progress we have made in understanding food allergy in children over the last five years," said Hugh Sampson, MD, Professor, Pediatrics, Chief, Division of Allergy & Immunology, Director of the Jaffe Food Allergy Institute, Mount Sinai School of Medicine and lead investigator on CoFAR. "With the renewal of this grant, we will expand our research and hopefully move closer toward ending the widespread impact of food allergy."

The grant will also fund new genetic research on eosinophilic gastrointestinal diseases (EGIDs), a new group of allergic diseases. According to the NIH, the most common EGID is eosinophilic esophagitis. The main symptoms in children include nausea, vomiting, and abdominal pain after eating. Three new CoFAR trial sites at Cincinnati Children's Medical Center Hospital, University of Colorado at Denver, and Children's Hospital of Philadelphia will conduct the research.

Dr. Sampson will remain principal investigator of the five original CoFAR sites: The Mount Sinai Medical Center, Duke University Medical Center, Johns Hopkins University, National Jewish Health in Denver, and University of Arkansas for Medical Sciences. CoFAR is currently enrolling patients for the trials evaluating treatment with peanut protein administered orally and through the skin patch.

Funding for CoFAR is provided by the National Institute of Allergy and Infectious Diseases and the National Institute of Diabetes and Digestive and Kidney Diseases, components of NIH.


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. The Marilyn B. Gula Mountains of Hope Foundation donates additional research funds to TGen
2. Chicago Father and Son Team to Climb Mount Kilimanjaro for ShelterBox
3. AAU Big Mountain Jam Basketball Tournament To Be Played On SnapSports Flooring
4. Mount Sinai researchers find structural basis for incidence of skin cancers in a genetic disorder
5. Women who consume large amounts of tea have increased risk of rheumatoid arthritis
6. Albeo Releases Six New Surface Mount LED Lighting Fixtures
7. Green Drinks NYC and Green Mountain Energy Company Present Summer Bash at Solar One
8. The Mount Sinai Hospital Ranked in Top 25 of Best Children's Hospitals in Two Specialties by U.S. News & World Report
9. Mount Sinai researchers approaching universal treatment for all strains of influenza
10. Mountain Retreat for Women Whose Lives Have Been Touched by Cancer
11. Mount Sinai researchers move closer to a universal influenza vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... On Friday, June ... a Bronze Wellness at Work award to iHire in recognition of their exemplary accomplishments ... of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... Francisco, CA (PRWEB) , ... June 24, 2016 ... ... CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive ... self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB ... Decision Making in Emergency Medicine conference in Ponte Vedra Beach, FL. The awards ... in Emergency Medicine Practice and Pediatric Emergency Medicine Practice. , “With ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
Breaking Medicine Technology: